Final Thoughts: GVHD
All panelists provide their final thoughts on the current landscape and future directions in graft-vs-host disease (GVHD).
Steroid-Refractory Chronic GVHD
Sophie Paczesny, MD, PhD, provides an overview of the drug ibrutinib for use in steroid-refractory chronic graft-vs-host disease (GVHD). She elicits thoughts from the panelists on how they envision this drug being used.
Steroid-Refractory Acute GVHD
Richard Maziarz, MD, provides an overview of the drug ruxolitinib, which was recently approved for use in steroid-refractory acute GVHD (graft-vs-host disease). He leads a discussion on the results of REACH-1 and REACH-2 and the experiences of the other panelists in using this drug.
Steroid Refractory GVHD: Scope of the Problem
Dr Chen provides an overview of the prevalence of steroid refractory GVHD and leads a discussion on how steroid refractory GVHD is defined.
Management of Chronic GVHD
Dr Cutler leads a discussion on the approach to management of chronic GVHD and whether complete response is a realistic end point.
Management of Acute GVHD
Yi-Bin Chen, MD, leads a discussion on systemic treatment approaches being used currently for the management of acute graft-vs-host disease, as well as those being considered for the future.
Diagnosing & Staging of GVHD
Sophie Paczesny, MD, PhD, leads a discussion on diagnostic tests used in the setting of graft-vs-host disease and how patients are risk stratified. Whether organ biopsies are used routinely is also discussed.
Richard Maziarz, MD, highlights the fact that graft-vs-host disease (GVHD) is a T-cell disease and then outlines qualitative and quantitative mechanisms that are used to prophylactically target the alloreactive T-cell population. A calcineurin inhibitor combined with methotrexate is the currently accepted standard of care for GVHD prophylaxis. Panelists weigh in on the use of post-transplant cyclophosphamide (PTCy) for prevention of GVHD.
Immunopathology and GVHD Incidence
Yi-Bin Chen , MD, provides an overview of how the landscape graft-vs-host disease (GVHD) has evolved over the past 3 decades. Corey Cutler, MD, PhD, FRCPC, provides an overview of GVHD biology. Potential risk factors for development of acute and chronic GVHD are discussed.
Unmet Needs in GVHD
Challenges and unmet needs in steroid-refractory GVHD and advice to community oncologists for the optimal management of disease.
Emerging Therapies for Acute and Chronic GVHD
Novel agents in the pipeline for the treatment of acute and chronic GVHD are discussed.
Treatment for Steroid-Refractory Chronic GVHD
A review of treatment options for patients with chronic GVHD who don’t respond to steroid therapy and preliminary findings from the phase 3 REACH3 trial.
Treatment for Steroid-Refractory Acute GVHD
Defining steroid-refractory acute GVHD, treatment options for patients who don’t respond to steroid therapy, and a review of the REACH2 trial.
Initial Therapy in GVHD
Experts in hematology-oncology share insights on approaching initial treatment and the treatment goals for acute and chronic GVHD.
Role of GVHD Prophylaxis
A discussion on the role of prophylactic therapy for patients after transplant as well as available options for GVHD prophylaxis.
Diagnosis of Acute and Chronic GVHD
Hematologist-oncologists review the typical presentation and diagnosis of acute and chronic GVHD and define how severity is classified.
Overview of Graft-Versus-Host Disease
Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, provide insight on the nature of graft-vs-host disease (GVHD) and common risk factors for acute and chronic GVHD.
Future Treatment Landscape of AML
Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Maintenance Therapy Post-Transplant in AML
Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.
Use of APR-246 and Oral HMAs in AML
Role of Transplant in AML
Use of Omidubicel Therapy in Hematologic Malignancies
BMT CTN 1102 Study in High-Risk MDS
Novel Targets and Biomarkers in AML
IDH1/2-Mutated Treatment-Naïve AML
BCL2 Inhibition in AML: VIALE-A Study
Type 1/2 FLT3 Inhibitors in AML
Role of Dual Targeted Therapy in AML
Sequencing of FLT3 Inhibitors in AML
Management of AML: FLT3 Inhibitors and BCL2 Inhibitors
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512